Growth Factors Release of PRF and PRGF

Periodontitis Clinical Trial

Official title:

Crevicular Fluid Growth Factors Release Profile Following the Use of Platelets Rich Fibrin (PRF) and Plasma Rich Growth Factors (PRGF) in Treating Periodontal Intrabony Defects (Randomized Clinical Trial)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02447510
• Other study ID #: Ain Shams Universty
• Status: Completed
• Phase: Phase 3
• First received: May 6, 2015
• Last updated: May 18, 2015
• Start date: September 2014
• Est. completion date: March 2015

Study information

• Verified date: May 2015
• Source: Al-Azhar University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Ministry of Higher Education
• Study type: Interventional

Clinical Trial Summary

Background: platelet concentrate could enhance growth factors (GF) crevicular fluid levels which might be crucial to proper tissue repair and wound healing. However, the open usually contaminated nature of periodontal defects could affect negatively GF availability and activity. To test this assumption, this study was designed to evaluate levels of VEGF and PDGF-BB in gingival crevicular fluid (GCF) during the early stages of healing of localized intrabony defects treated with platelet rich in growth factor (PRGF) and platelet rich fibrin (PRF) as compared with xenograft defect filling control.

Methods: Thirty non-smoking patients with severe chronic periodontitis participated in this prospective, randomized and single blinded trial. Each patient contributed one interproximal defect that was randomly assigned to the bone substitute grafting control (n=10) G1, experimental PRGF (n=10) G2 and PRF (n=10) G3. Plaque index, gingival index, probing depth (PD), clinical attachment level (CAL) and the intrabony depth of the defect (IBD) were measured at baseline for patient enrollment. Gingival crevicular fluid (GCF) samples were collected on days 1 and 3, 7, 14, 21, and 30 days after therapy. The primary outcome variable was the change in VEGF and PDGF-BB levels for sites treated by PRGF and PRF compared to that of the xenograft treated cases.

Description:

Owing to the lots of challenges that facing the use of recombinant growth factors in periodontal therapy, it is important to look for an alternative that combine ease of preparation and physiologic mode of delivery. Platelet concentrate has been developed for this purpose with many debates about the duration of GF availability in the defect area. Platelet-rich fibrin (PRF) is a leucocyte- and platelet-rich fibrin biomaterial. This dense fibrin membrane was claimed to releases high quantities of three main growth factors (Transforming Growth Factor b-1 (TGFβ-1), platelet derived growth factor AB, PDGF-AB; vascular endothelial growth factor, VEGF) and an important coagulation matricellular glycoprotein (thrombospondin-1, TSP-1). It has a natural fibrin framework that can protect growth factors from proteolysis. It is shown that PRF can release growth factors gradually and keep their activity to a relatively long period compared with platelet rich plasma (PRP). Levels of released TGF-1 and PDGF-AB markedly increased and reached the highest amount at day , then decreased mildly. In contrast, PRP experienced uncontrollable and short-term release of TGF-1 and PDGF-AB, which reached the highest amount at day 1 and then decreased rapidly.Clinically, it was found that PRF can improve clinical parameters associated with human intrabony periodontal defects and BPBM (bovine porous bone mineral) has the ability to augment effects of PRF in reducing pocket depth, improving clinical attachments levels, and promoting defect fill. On the other hand studies reported similar PD (probing depth) reduction, CAL (clinical attachment level) gain, and bone fill at sites treated with PRF or PRP compared with conventional open flap debridement.

Preparation rich in growth factors (PRGF-Endoret) technology was claimed to circumvent many of the limitations of other reported platelet-rich preparations. Sodium citrate and calcium chloride are used as an anticoagulant and a clot activator, respectively. Addition of calcium chloride promotes the formation of native thrombin, mimicking the physiological clotting process and enabling a more sustained release of growth factors, which might be crucial to proper tissue repair and wound healing. Moreover, this procedure obviates immunological reactions and the risk of disease transmission associated with the use of exogenous bovine thrombin. Anitua et al reported that PRGF contains a moderately elevated platelet concentration of ~6x105 platelets, which has been reported to induce the optimal biological benefit. Lower platelet concentrations can lead to suboptimal effects, whereas higher concentrations might have an inhibitory effect. PRGF application after extraction improved the healing process in diabetic patients by accelerating socket closure (epithelialization) and tissue maturation, proving the association between PRGF use and improved wound healing in diabetic patients.

In the present study it was proposed that the opened, constantly contaminated nature periodontal defects could be a source of continuous catabolic bacterial and tissue enzymes and binding proteins that affect platelet concentrate contained GF availability and activity. To confirm this assumption, this study was designed to evaluate levels of platelet derived growth factor - BB (PDGF-BB) and vascular endothelial cell growth factor (VEGF) in GCF during the early stages of healing for sites treated with PRF and PRGF in intrabony periodontal defects and to correlate GF levels with the clinical findings. This could figure out the potentials of these 2 commonly used platelet concentrate in the periodontal defects ecology.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 25 Years to 55 Years

Eligibility

Inclusion Criteria:

1. no systemic diseases which could influence platelet concentration or the outcome of therapy;

2. good compliance with plaque control instructions following initial therapy;

3. teeth involved were all vital with no mobility ;

4. each subject contributed a single predominately 2 or 3-wall intrabony interproximal defect around premolar or molar teeth without furcation involvement;

5. selected intrabony defects (IBDs) measured from the alveolar crest to the defect base in diagnostic periapical radiographs of = 3 mm;

6. selected probing depth (PD) = 6 mm and clinical attachment loss (CAL) = 5 mm at the site of intraosseous defects four weeks following initial cause-related therapy;

7. availability for the follow-up and maintenance program;

8. absence of periodontal treatment during the previous year;

9. absence of systemic medications that could affect healing or antibiotic treatment during the previous 6 months; and

10. absence of occlusal interferences or open interproximal contacts (diastema, flaring or both).

Exclusion Criteria:

1. smokers and Pregnant females were excluded from participating in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Periodontitis

Intervention

Procedure:
• group 1 bio-oss bone xenograft
bone substitute (bio-oss)
• group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)
platelet rich in growth factor (autogenous platelet rich in growth factor)
• group 3 platelet rich fibrin (autogenous platelet rich fibrin)
platelet rich fibrin (autogenous platelet rich fibrin)

Locations

Country	Name	City	State
Egypt	Ain Shams Universty	Cairo	Nasr City

Sponsors (1)

Lead Sponsor	Collaborator
Al-Azhar University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy parameters for the study were the crevicular fluid VEGF and PDGF-BB levels at 1 day		1 day	Yes
Primary	crevicular fluid VEGF and PDGF-BB levels at 3day		3 days	Yes
Primary	crevicular fluid VEGF and PDGF-BB levels at 7 day		7 days	Yes
Primary	crevicular fluid VEGF and PDGF-BB levels at 14 day		14 days	Yes
Primary	crevicular fluid VEGF and PDGF-BB levels at 21 day		21 days	Yes
Primary	crevicular fluid VEGF and PDGF-BB levels at 30 day		30 days	Yes
Secondary	Secondary efficacy parameters included pocker depth at 6 months after surgery.		6 months	Yes
Secondary	Secondary efficacy parameters included pocker depth at 9 months after surgery.		9 months	Yes
Secondary	Secondary efficacy parameters included radiographic intrabony defect depth measurements 9 months after surgery.		9 months	Yes
Secondary	Secondary efficacy parameters included clinical attachment level at 6 months after surgery.		6 months	Yes
Secondary	Secondary efficacy parameters included clinical attachment level at 9 months after surgery.		9 months	Yes